Study design, treatment schema, and subgroups.^aSC dose adjustments were not permitted. ^bPer protocol and zoledronic acid label, IV product was dose adjusted for baseline CrCl, and subsequent dose intervals were determined by serum creatinine levels. PBSC, peripheral blood stem cell; Q4W, every 4 weeks; SC, subcutaneous.